---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-24-000146"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:33:23.183921+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Q2 net loss $445M; revs up 9% to $1.04B; Jakafi guidance raised; $2B buyback completed

## Summary
- Total revenues $1,044M (+9% YoY); Jakafi $706M (+3%), Opzelura $122M (+52%).
- GAAP net loss $444.6M vs $203.5M income in Q2 2023; non-GAAP net loss $396.1M.
- Completed $2.0B share repurchase (33.3M shares at $60 each) in June 2024.
- Raised low end of 2024 Jakafi revenue guidance to $2,710-$2,750M; revised R&D guidance up.
- Discontinued development of oral PD-L1, LAG-3, TIM-3, LAG-3xPD-1; focus on high-impact programs.

## SEC filing metadata
- accession: 0000879169-24-000146
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916924000146/0000879169-24-000146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916924000146/incy-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-24-000146
- JSON: https://secwatch.observer/filing/0000879169-24-000146.json
- Plain text: https://secwatch.observer/filing/0000879169-24-000146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.